[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634382":3},{"organization":4,"outcomesModule":7,"designInfo":40,"detailedDescription":43,"studyPopulation":44,"armGroups":39,"interventions":39,"overallOfficials":39,"centralContacts":45,"locations":51,"responsibleParty":74,"collaborators":39,"id":77,"slug":78,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":39,"eligibilityCriteria":83,"healthyVolunteers":79,"sex":84,"minAge":85,"maxAge":39,"enrollmentInfo":86,"targetDuration":39,"studyType":89,"phases":39,"briefSummary":90,"conditions":91,"keywords":95,"overallStatus":100,"whyStopped":39,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Caja Costarricense de Seguro Social","OTHER_GOV",{"primaryOutcomes":8,"secondaryOutcomes":17,"otherOutcomes":39},[9,13],{"measure":10,"description":11,"timeFrame":12},"Characterize the epidemiology","Characterize the epidemiology of patients diagnosed with cutaneous T-cell lymphoma evaluated in the Dermatology Service of Hospital México.","2019-2025",{"measure":14,"description":15,"timeFrame":16},"Characterize the therapeutic management","Characterize the therapeutic management of patients diagnosed with cutaneous T-cell lymphoma evaluated in the Dermatology Service of Hospital México","2019-2025.",[18,21,24,27,30,33,36],{"measure":19,"description":20,"timeFrame":12},"Describe the sociodemographic\u002Fepidemiological characteristics","To describe the sociodemographic and epidemiological characteristics of patients diagnosed with cutaneous T-cell lymphoma evaluated in the Dermatology Service of Hospital México during the period from 2019 to 2025.",{"measure":22,"description":23,"timeFrame":12},"Classify the clinical manifestations\u002Fclinical subtypes","Classify the clinical manifestations and clinical subtypes of cutaneous T-cell lymphoma present in the studied population.",{"measure":25,"description":26,"timeFrame":12},"Identify the histopathological\u002F immunohistochemical findings","To identify the histopathological and immunohistochemical findings associated with cutaneous T-cell lymphoma in the included patients.",{"measure":28,"description":29,"timeFrame":12},"Analyze the therapeutic management modalities.","Analyze the therapeutic management modalities used, including skin-directed therapies and their outcomes.",{"measure":31,"description":32,"timeFrame":12},"identify the clinical stage at the time of diagnosis","identify the clinical stage of the disease at the time of diagnosis according to the TNMB staging system.",{"measure":34,"description":35,"timeFrame":12},"Evaluation of imaging studies and laboratory.","Evaluate imaging studies and laboratory findings of patients with cutaneous T-cell lymphoma during the follow-up period.",{"measure":37,"description":38,"timeFrame":12},"Evaluation of clinical course and outcomes.","Evaluation of clinical course and outcomes of patients with cutaneous T-cell lymphoma during the follow-up period.",null,{"allocation":39,"interventionModel":39,"interventionModelDescription":39,"primaryPurpose":39,"observationalModel":41,"timePerspective":42,"maskingInfo":39},"COHORT","RETROSPECTIVE","This retrospective observational study will analyze adult patients (≥18 years) with a confirmed diagnosis of cutaneous T-cell lymphoma evaluated in the Dermatology Service of Hospital México between January 2019 and December 2025. Data will be obtained from electronic medical records (EDUS), including sociodemographic characteristics, clinical presentation, histopathological and immunohistochemical findings, disease staging, treatment modalities, and clinical outcomes.\n\nPatients must have at least one documented dermatological evaluation and have received treatment, including skin-directed therapies and\u002For systemic therapies. Records that are incomplete, inconsistent, or lack histopathological confirmation will be excluded.\n\nThe study aims to characterize local epidemiological and therapeutic patterns and describe clinical outcomes using descriptive statistical analysis, providing updated real-world evidence to support clinical decision-making and optimize management strategies for cutaneous T-cell lymphoma in a national referral center.","he study population will consist of adult patients (≥18 years) of both sexes with a confirmed diagnosis of cutaneous T-cell lymphoma, established through clinical, histopathological, and immunohistochemical criteria, and documented in EDUS at the Dermatology Service of Hospital México between January 2019 and December 2025. Patients must have at least one recorded dermatological evaluation during the study period and must have received some form of treatment, including skin-directed therapies (phototherapy, topical treatments, localized radiotherapy) and\u002For systemic therapies.\n\nPatients with insufficient or incomplete clinical records that prevent adequate diagnostic classification, staging, therapeutic characterization, or evaluation of clinical evolution will be excluded, as well as those with a presumptive diagnosis without histopathological confirmation, duplicate or inconsistent records, patients attended outside the study period, those outside the defined age range, and patients.",[46],{"name":47,"role":48,"phone":49,"phoneExt":39,"email":50},"Daniel Barquero-Orias, Dermatologist","CONTACT","+506 83411026","debarque@ccss.sa.cr",[52],{"facility":53,"status":39,"city":54,"state":55,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"Hospital México","San José","Uruca","10107","Costa Rica","CR",{"type":60,"coordinates":61},"Point",[62,63],-84.08489,9.93388,{"lat":63,"lon":62},[66,67,70,73],{"name":47,"role":48,"phone":49,"phoneExt":39,"email":50},{"name":68,"role":69,"phone":39,"phoneExt":39,"email":39},"Raquel Ramirez-Fallas, Dermatology Resident","PRINCIPAL_INVESTIGATOR",{"name":71,"role":72,"phone":39,"phoneExt":39,"email":39},"Said Fallas-Moya, Dermatologist","SUB_INVESTIGATOR",{"name":47,"role":72,"phone":39,"phoneExt":39,"email":39},{"type":69,"investigatorFullName":75,"investigatorTitle":76,"investigatorAffiliation":5,"oldNameTitle":39,"oldOrganization":39},"Daniel Barquero Orias","Dermatologist","100634382","epidemiology-and-management-of-cutaneous-t-cell-lymphoma-at-hospital-mxico-costa-rica-100634382",false,"NCT07538960","Epidemiology and Management of Cutaneous T-Cell Lymphoma at Hospital México, Costa Rica.","Epidemiological Profile and Therapeutic Management of Patients Diagnosed With Cutaneous T-cell Lymphoma Evaluated in the Dermatology Department of Hospital México During the Period From 2019 to 2025.","Inclusion Criteria:\n\n* Patients with a confirmed diagnosis of cutaneous T-cell lymphoma, established through clinical, histopathological, and immunohistochemical criteria, documented in EDUS of Hospital México in the Dermatology Service of Hospital México during the period between January 2019 and December 2025.\n* Patients aged 18 years or older, of both sexes.\n* Patients with at least one dermatological evaluation recorded during the study period.\n* Patients who, having a confirmed diagnosis, have received some modality of treatment, including skin-directed therapies (phototherapy, topical treatments, localized radiotherapy) and\u002For systemic treatments.\n\nExclusion Criteria:\n\n* Clinical records that are insufficient or incomplete, preventing adequate diagnostic classification, staging, therapeutic characterization, or evaluation of clinical evolution.\n* Patients with a presumptive diagnosis of cutaneous T-cell lymphoma without histopathological confirmation.\n* Duplicate or inconsistent records that hinder the correct identification and classification of the patient.\n* Patients attended outside the established study period.\n* Patients outside the age range.\n* Patients who do not belong to the Dermatology Service of Hospital México.","ALL","18 Years",{"count":87,"type":88},350,"ESTIMATED","OBSERVATIONAL","Adult patients (≥18 years) with confirmed cutaneous T-cell lymphoma evaluated at Hospital México between 2019 and 2025 will be retrospectively analyzed using EDUS records to describe their epidemiological profile, clinical characteristics, treatments, and outcomes.",[92,93,94],"Lymph Node Cancer","Cutaneous","T-cell Lymphoma",[96,97,98,99],"Linfoma","Cutaneous Lymphoma","T-Cell Lymphoma","Therapy","NOT_YET_RECRUITING","2026-04-13",{"date":103,"type":104},"2026-04-20","ACTUAL",{"date":106,"type":88},"2026-05",{"date":108,"type":88},"2027-05",{"name":5,"class":6},1]